NEUVIOR is building the medicines action layer for modern health systems.
PHARMORIS helps health systems turn fragmented medicines signals into prioritised action, decision-grade evidence and tracked execution across pharmacy, finance, procurement and providers. We are currently raising a focused pre-seed bridge to convert external validation into paid NHS pilot proof and seed readiness.
£21.6bn
NHS prescribing costs in 2024/25
~£1.4bn
Biological medicines due off patent by 2028
Up to £1bn
Potential savings window from timely best-value biological uptake
Validated
2 Innovate UK wins + 1 SMART:Scotland award
Turning NHS data signals into approved, tracked actions within one budget cycle
NEUVIOR builds execution infrastructure for healthcare value delivery. PHARMORIS is our first product: a decision-support platform that converts medicines-value signals into stakeholder-ready actions, eliminating the 18-24 month gap between insight and implementation.
NHS organisations have data but lack execution infrastructure. PHARMORIS provides the workflow layer that turns fragmented signals into approved, trackable actions.
Execution pressure is rising. Buyers are being pushed to deliver measurable productivity and cost improvement, not just identify theoretical opportunities.
Large medicines-value windows are time-bound. Organisations that can prioritise, socialise and execute quickly will capture more value.
Why Now: The Window for Execution Infrastructure
Budget Pressure
NHS deficit reached £2.2bn in 2024. Trusts must act on known savings opportunities—not wait for new insights.
Digital Mandate
2025 NHS policy shift toward digital-first procurement creates first-mover advantage for proven execution tools over legacy analytics platforms.
Justify
Builds decision-grade evidence for pharmacy, finance and leadership.
Deploy
Turns approved opportunities into owned action with clear accountability.
Track
Measures progress, closure and realised value over time.
Not another dashboard. Not a replacement for BI. The layer between insight and action.
What We're Building: PHARMORIS Platform
Decision-support infrastructure that ingests signals, prioritizes by execution complexity, and routes actions through stakeholder approval.
Signal Ingestion
Trust and ICB pharmacy leaders, medicines teams and finance stakeholders responsible for delivering value and productivity.
How it lands first
A tightly scoped engagement that turns fragmented signals into one short list of approved actions, evidence, ownership and tracked follow-through.
Why it gets bought
Low-friction, measurable and tied to work buyers already have to deliver.
Key Milestones & Validation Already Achieved
NEUVIOR has de-risked technical, commercial, and regulatory pathways through institutional backing and structured proof-of-concept work. This pre-seed capital accelerates from validation to live NHS pilots and referenceable commercial evidence..
Innovate UK Backing
Secured competitive Innovate UK awards validating technical feasibility, market need, and NHS relevance—providing non-dilutive capital and institutional credibility with clinical decision-makers.
Clean asset base
PHARMORIS sits inside NEUVIOR Pharmaceuticals Ltd with core grants, IP and trademarks held in one operating entity.
Market access in motion
NHS-facing routes and buyer conversations are shaping the first pilot structures.
Bridge objective
Convert validation into paid pilot proof, case studies and seed-ready commercial evidence.
Market Opportunity: Narrow Wedge, Expanding Footprint
Win the first NHS wedge in medicines-value execution. Then expand the same decision-support infrastructure into neighbourhood delivery, community pharmacy, care pathways, and integrated care systems—each proven success funding the next expansion.
Trusts and ICBs
Win the first NHS wedge where medicines-value execution is already a live buyer problem.
Cross-setting execution
Expand the same workflow across neighbourhood delivery, community pharmacy and wider stakeholder groups.
Wider health systems
Take the same operating model into broader payer-provider environments over time.
NHS-first, not NHS-only.
Pre-Seed Capital: Bridge to Pilot Proof & Seed Readiness
NEUVIOR is raising a targeted pre-seed round from aligned angels, healthcare-focused funds, and strategic operators. This capital converts institutional validation into live NHS pilots, referenceable commercial proof, and the traction metrics institutional seed investors require.
Platform Hardening
Finalize production-grade platform security, NHS data compliance (DSPT), and integration readiness for pilot deployment without technical blockers.
What it should prove
Paid pilot environments, first referenceable case study, annual contract path and seed-ready diligence.
Who we want to hear from
Investors who understand healthcare infrastructure, health systems software, AI-enabled workflow or regulated delivery.
The next round prices proof. This round creates it.
Validated & Ready
Pre-seed bridge open to aligned investors
Join us in transforming NHS medicines execution
We're speaking with aligned investors who understand the strategic importance of healthcare infrastructure and the execution gap in NHS medicines value delivery.
Non-dilutive validation secured
Multiple grants and institutional awards validate market need
Clear path to pilot revenue
NHS buyer conversations active, first pilots being structured
Focused capital deployment
Bridge designed to prove seed-ready metrics and commercial traction
Request Investor Deck & Data Room Access
Financial models, Innovate UK validation docs, pilot frameworks, and technical architecture are available to qualified investors. Submit your details below.
Frequently Asked Questions
Ready to learn more?
Request investor materials or speak with our team to discuss the PHARMORIS opportunity.